All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Join our
Treating classical Hodgkin lymphoma: Spotlight on targeted therapies
with Gilles Salles, Paul Bröckelmann, and Ann S. LaCasce
Saturday, November 2, 2024
8:50-9:50 CET
This independent educational activity is sponsored by Takeda. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
Frailty tools are often used in the assessment of patients with multiple myeloma (MM) to identify those who are at the highest risk for treatment intolerance, toxicity, and early mortality. Patients determined as frail are less frequently prescribed intense or ‘aggressive’ treatments, including those with some of the highest rates of response and overall survival. It is therefore vital to accurately categorize patients by frailty to prevent over- or under-treatment that could result in poorer outcomes.
Here, we summarize a publication by Murugappan et al.1 comparing the patient-reported frailty phenotype (PRFP) and the International Myeloma Working Group Frailty Index (IMWG FI) approaches to measuring frailty.
Table 1. Classification of frailty by IMWG FI and PRFP tools*
Frailty status, % |
IMWG FI |
PRFP |
---|---|---|
Frail |
16.4 |
21.7 |
Intermediate/pre-frail |
28.1 |
24.5 |
Fit |
55.5 |
53.8 |
IMWG FI, International Myeloma Working Group Frailty Index; PRFP, patient-reported frailty phenotype. |
Figure 1. Overlap in categorization of frailty by the IMWG FI and the PRFP*
IMWG, International Myeloma Working Group; PRFP, patient-reported frailty phenotype.
*Adapted from Murugappan, et al.1
Key learnings |
---|
|
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox